ES547051A0 - Procedimiento para obtener complejos fviii-vwf para uso te- rapeutico - Google Patents

Procedimiento para obtener complejos fviii-vwf para uso te- rapeutico

Info

Publication number
ES547051A0
ES547051A0 ES547051A ES547051A ES547051A0 ES 547051 A0 ES547051 A0 ES 547051A0 ES 547051 A ES547051 A ES 547051A ES 547051 A ES547051 A ES 547051A ES 547051 A0 ES547051 A0 ES 547051A0
Authority
ES
Spain
Prior art keywords
fviii
vwf
complex
procedure
therapeutic use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES547051A
Other languages
English (en)
Other versions
ES8700568A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunotech SAS
Original Assignee
Immunotech SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunotech SAS filed Critical Immunotech SAS
Publication of ES547051A0 publication Critical patent/ES547051A0/es
Publication of ES8700568A1 publication Critical patent/ES8700568A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16L—PIPES; JOINTS OR FITTINGS FOR PIPES; SUPPORTS FOR PIPES, CABLES OR PROTECTIVE TUBING; MEANS FOR THERMAL INSULATION IN GENERAL
    • F16L55/00—Devices or appurtenances for use in, or in connection with, pipes or pipe systems
    • F16L55/26—Pigs or moles, i.e. devices movable in a pipe or conduit with or without self-contained propulsion means
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N5/00—Details of television systems
    • H04N5/76—Television signal recording
    • H04N5/91—Television signal processing therefor
    • H04N5/92—Transformation of the television signal for recording, e.g. modulation, frequency changing; Inverse transformation for playback
    • H04N5/9201—Transformation of the television signal for recording, e.g. modulation, frequency changing; Inverse transformation for playback involving the multiplexing of an additional signal and the video signal
    • H04N5/9206—Transformation of the television signal for recording, e.g. modulation, frequency changing; Inverse transformation for playback involving the multiplexing of an additional signal and the video signal the additional signal being a character code signal
    • H04N5/9207—Transformation of the television signal for recording, e.g. modulation, frequency changing; Inverse transformation for playback involving the multiplexing of an additional signal and the video signal the additional signal being a character code signal for teletext
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Signal Processing (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Multimedia (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Combustion & Propulsion (AREA)
  • Zoology (AREA)
  • Mechanical Engineering (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES547051A 1984-09-18 1985-09-17 Procedimiento para obtener complejos fviii-vwf para uso te- rapeutico Expired ES8700568A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8414480A FR2570276B1 (fr) 1984-09-18 1984-09-18 Procede d'obtention du complexe fviii/vwf a usage therapeutique et produits en resultant

Publications (2)

Publication Number Publication Date
ES547051A0 true ES547051A0 (es) 1986-10-16
ES8700568A1 ES8700568A1 (es) 1986-10-16

Family

ID=9307917

Family Applications (1)

Application Number Title Priority Date Filing Date
ES547051A Expired ES8700568A1 (es) 1984-09-18 1985-09-17 Procedimiento para obtener complejos fviii-vwf para uso te- rapeutico

Country Status (9)

Country Link
US (1) US4670543A (es)
EP (1) EP0179006B1 (es)
JP (2) JPH0649720B2 (es)
AT (1) ATE69955T1 (es)
CA (1) CA1257211A (es)
DE (1) DE3584817D1 (es)
ES (1) ES8700568A1 (es)
FR (1) FR2570276B1 (es)
WO (1) WO1986001718A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543145A (en) * 1984-09-17 1996-08-06 Baxter International, Inc. Pharmaceutical composition and method for the suppression of factor VIII inhibitor production
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
DE3707213A1 (de) * 1987-03-06 1988-09-15 Behringwerke Ag Verfahren zur herstellung von faktor viii:c-mangelplasma und ein so erhaltenes mangelplasma
US5177191A (en) * 1987-12-21 1993-01-05 Miles, Inc. Gel filtration of factor VIII
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
FR2665449B1 (fr) * 1990-08-02 1995-04-14 Aquitaine Developp Transf Sang Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant.
US5760183A (en) * 1989-02-17 1998-06-02 Association D'aquitaine Pour De Developpment De La Transfusion Sanguine Et Des Recherches Hematologiques Process for the manufacture of very high-purity antithaemophilic factor (FVIIIC), and von Willebrand factor, and pharmaceutical compositions containing same
US5110907A (en) * 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
JPH0427865A (ja) * 1989-12-21 1992-01-30 Kurita Water Ind Ltd 血液凝固因子用分離剤およびその製造方法
AT403991B (de) * 1990-04-04 1998-07-27 Atomic Austria Gmbh Alpinschi
AT403992B (de) * 1991-02-22 1998-07-27 Head Sport Ag Ski
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT403765B (de) * 1996-04-12 1998-05-25 Immuno Ag Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex
AT406867B (de) 1997-02-27 2000-10-25 Immuno Ag Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
US20060068454A1 (en) * 2004-09-27 2006-03-30 Sysmex Corporation Method of inactivating blood coagulation factor and blood coagulation factor-inactivated sample

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies

Also Published As

Publication number Publication date
WO1986001718A1 (fr) 1986-03-27
FR2570276B1 (fr) 1987-09-04
ES8700568A1 (es) 1986-10-16
JPH0649720B2 (ja) 1994-06-29
FR2570276A1 (fr) 1986-03-21
JPS62500520A (ja) 1987-03-05
DE3584817D1 (de) 1992-01-16
EP0179006B1 (fr) 1991-12-04
US4670543A (en) 1987-06-02
EP0179006A1 (fr) 1986-04-23
JPH06102680B2 (ja) 1994-12-14
JPH06107700A (ja) 1994-04-19
ATE69955T1 (de) 1991-12-15
CA1257211A (fr) 1989-07-11

Similar Documents

Publication Publication Date Title
ES547051A0 (es) Procedimiento para obtener complejos fviii-vwf para uso te- rapeutico
KR880700061A (ko) 인체 암종양과 관련된 항원에 대한 단클론성 항체
IT1160468B (it) Procedimento per la produzione di anticorpi monoclonali umani
DE3573922D1 (en) Monoclonal antibody directed to human ganglioside gd 2?
EP0359063A3 (en) Antibody having high affinity to hapten as antigen and immunogen for obtaining the same
GR900100221A (en) Novel monoclonic antibodies against a new antigen relating to human tumours
SE8401942L (sv) Anti-tumorsubstans och forfarande for framstellning av densamma
FI930580A (fi) Tri- och tetravalensiska monopecifika antigen bindande proteiner
DK382989D0 (da) Cytotoxiske vinca-konjugater bundet til antistoffer og fremgangsmaade til fremstilling deraf
NO169021C (no) Fremgangsmaate for fremstilling av vesentlig rent uglykosylert humant interleukin-2-protein
IT1207589B (it) Composizione di anticorpi monoclonali umani cross-protettivi.
HUT43104A (en) Process for producing human antibodies
SE8103198L (sv) Forfarande for framstellning av antikroppar
GB2083836A (en) Monoclonal antibody
JPS55136235A (en) Antitumor protein complex and its preparation
SE8404283D0 (sv) Anvendning av ett specifikt tumorassocierat antigen, nemligen sialosyllaktotetraos, for diagnostiska och terapeutiska forfaranden vid cancersjukdomar
KR890700683A (ko) 인체 면역 결핍 바이러스에 대한 항체 검색 방법
EP0460607A3 (en) Novel monoclonal antibody to novel antigen associated with human tumors
PT86960A (pt) Process for the preparation of immunoglobulin conjugates
KR880701686A (ko) 페라이트 원료용 분말 복합 산화물의 제조방법
FI92716C (fi) Uudet monoklonaaliset vasta-aineet IFN-omegalle, niiden valmistusmenetelmät ja niiden käyttö IFN-omegan puhdistamiseen ja osoittamiseen
IT8967049A0 (it) Anticorpo umano monoclonale composizione terapeutica che lo contiene linea cellulare capace di produrre l anticorpo procedimento per la suaproduzione
ZA905295B (en) Production of antigens by self-assembly of polypeptide components
GR910300049T1 (en) Use of human immunoglobulins g or their fc fragments thereof as a medicament preparatory to the administration of monoclonal antibodies to man
ZA87863B (en) Cross-protective human monoclonal antibody compositions